Nebivolol [Lobivon, Nebilet, Nebilox, Solistar] reduces mortality and morbidity in elderly patients with chronic heart failure, according to the results of the SENIORS study presented at the 26th Annual Congress of the European Society of Cardiology (ESC) [Munich, Germany; August-September 2004]. Patients aged ≥ 70 years receiving nebivolol had a significantly reduced risk of all-cause mortality and cardiovascular hospital admissions, compared with placebo recipients. The effects seen were similar across subgroups with respect to age, gender and ejection fraction.